drugset
drugset / Trial / NCT02408185

Optimization Dose Study on Pharmacokinetics and Pharmacodynamics of Colistin in Critically Ill Patients

NCT02408185 ↗

Phase 1 Completed 20 enrolled Andalusian Public Foundation for Health Research in Seville
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Phase II clinical trial, open-labelled, prospective and single-center study directed to obtain blood samples in experimental detailed conditions in order to compare and optimize the dose of colistin in critically ill patients suffering from infections on which the indication of colistin would be accepted according to normal local protocols for severe infections treatment.

Timeline

Start
2011-10
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Colistin Other / unclassified 240 mg —
Subject Colistin Other / unclassified 360 mg —

Indications

No indication recorded.